서울대학교 중앙도서관

S-Space 소개

My S-Space

로그인이 필요합니다.

Login

S-Space

Browse

Subject

Jump to a point in the index

Or type in a year

Sort by
In order
Results/Page
Authors/record

Showing results 1 to 15 of 15

Issue Date	Title / Author(s) / Citation	File	Altmetrics
2001-04	A phase I study of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-1,3-dioxolane] platinum(II) in patients with advanced malignancies Kim, Noe Kyeong; Kim, Tae‐You; Shin, Sang‐Goo; Park, Young Iee; Lee, Jung Ae; Cho, Yong‐Baik; Kim, Key H.; Kim, Dae‐Kee; Heo, Dae Seog; Bang, Yung‐Jue Cancer, Vol.91 No.8, pp.1549-1556	DOI
2006-04	Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation Han, Sae-Won; Kim, Tae-You; Jeon, Young Kyung; Hwang, Pil Gyu; Im, Seock-Ah; Lee, Kyung-Hun; Kim, Jee Hyun; Kim, Dong-Wan; Heo, Dae-Seog; Kim, Noe Kyeong; Chung, Doo Hyun; Bang, Yung-Jue Clinical Cancer Research, Vol.12 No.8, pp.2538-2544	DOI
2007-04	Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy Lee, Kyung-Hun; Im, Seock-Ah; Oh, Do-Youn; Lee, Se-Hoon; Chie, Eui Kyu; Han, Wonshik; Kim, Dong-Wan; Kim, Tae-You; Park, In Ae; Noh, Dong-Young; Heo, Dae Seog; Ha, Sung Whan; Bang, Yung-Jue BMC Cancer, Vol.7, p. 63	view file DOI
2009-07	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI Yi, Hyeon Gyu; Kim, Hye Jin; Kim, Yu Jung; Han, Sae-Won; Oh, Do-Youn; Lee, Se-Hoon; Kim, Dong-Wan; Im, Seock-Ah; Kim, Tae-You; Kim, Chul Soo; Heo, Dae Seog; Bang, Yung-Jue Lung Cancer, Vol.65 No.1, pp.80-84	DOI
2009-08	Erlotinib after Gefitinib failure in female never-smoker Asian patients with pulmonary adenocarcinoma Sim, Sung Hoon; Han, Sae-Won; Oh, Do-Youn; Lee, Se-Hoon; Kim, Dong-Wan; Im, Seock-Ah; Chung, Doo Hyun; Kim, Tae-You; Lee, Jong Seok; Kim, Young Whan; Heo, Dae Seog; Bang, Yung-Jue Lung Cancer, Vol.65 No.2, pp.204-207	DOI
2009-09	Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells Yoon, Young-Kwang; Kim, Hwang-Phill; Han, Sae-Won; Hur, Hyung-Seok; Oh, Do Youn; Im, Seock-Ah; Bang, Yung-Jue; Kim, Tae-You Molecular Cancer Therapeutics, Vol.8 No.9, pp.2526-2536	DOI
2010-03	Expression of Class III Beta-Tubulin Correlates with Unfavorable Survival Outcome in Patients with Resected Non-small Cell Lung Cancer Koh, Youngil; Jang, Bogun; Han, Sae-Won; Kim, Tae-Min; Oh, Do-Youn; Lee, Se-Hoon; Kang, Chang Hyun; Kim, Dong-Wan; Im, Seock-Ah; Chung, Doo Hyun; Kim, Young Tae; Kim, Tae-You; Kim, Young-Whan; Kim, Joo Hyun; Heo, Dae Seog; Bang, Yung-Jue Journal of Thoracic Oncology, Vol.5 No.3, pp.320-325	DOI
2010-04	KRAS Mutant Lung Cancer Cells Are Differentially Responsive to MEK Inhibitor Due to AKT or STAT3 Activation: Implication for Combinatorial Approach Yoon, Young-Kwang; Kim, Hwang-Phill; Han, Sae-Won; Oh, Do Youn; Im, Seock-Ah; Bang, Yung-Jue; Kim, Tae-You Molecular Carcinogenesis, Vol.49 No.4, pp.353-362	DOI
2010-06	The relationship between response to previous systemic treatment and the efficacy of subsequent pemetrexed therapy in advanced non-small cell lung cancer Sun, Jong-Mu; Oh, Do-Youn; Lee, Se-Hoon; Kim, Dong-Wan; Im, Seock-Ah; Kim, Tae-You; Lee, Jong Seok; Kim, Young-Whan; Heo, Dae Seog; Bang, Yung-Jue Lung Cancer, Vol.68 No.3, pp.427-432	DOI
2011-03	Antitumor activity of HM781-36B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer Nam, Hyun-Jin; Kim, Hwang-Phill; Yoon, Young-Kwang; Hur, Hyung-Seok; Song, Sang-Hyun; Kim, Maeng-Sup; Lee, Gwan-Sun; Han, Sae-Won; Im, Seock-Ah; Kim, Tae-You; Oh, Do-Youn; Bang, Yung-Jue Cancer Letters, Vol.302 No.2, pp.155-165	DOI
2012-07	Breast density change as a predictive surrogate for response to adjuvant endocrine therapy in hormone receptor positive breast cancer Kim, Jisun; Han, Wonshik; Moon, Hyeong-Gon; Ahn, Soo Kyung; Shin, Hee-Chul; You, Jee-Man; Han, Sae-Won; Im, Seock-Ah; Kim, Tae-You; Koo, Hye Ryoung; Chang, Jung Min; Cho, Nariya; Moon, Woo Kyung; Noh, Dong-Young Breast Cancer Research, Vol.14 No.4, p. R102	view file DOI
2015-03	Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells Min, Ahrum; Im, Seock-Ah; Kim, Debora Keunyoung; Song, Sang-Hyun; Kim, Hee-Jun; Lee, Kyung-Hun; Kim, Tae-Yong; Han, Sae-Won; Oh, Do-Youn; Kim, Tae-You; O'Connor, Mark J.; Bang, Yung-Jue Breast Cancer Research, Vol.17, p. 33	view file DOI
2017-01	Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment An, Eunkyung; Ock, Chan Young; Kim, Tae You; Lee, Kyung Hun; Han, Se Won; Im, Seock Ah; Kim, Tae Yong; Liao, Wei Li; Cecchi, Fabiola; Blackler, Adele; Thyparambil, Sheeno; Kim, W. H.; Burrows, Jon; Hembrough, Todd; Catenacci, Daniel V.T.; Oh, Do Youn; Bang, Yung–Jue Annals of Oncology, Vol.28 No.1, pp.110-115	DOI
2020	Tumor immune profiles noninvasively estimated by FDG PET with deep learning correlate with immunotherapy response in lung adenocarcinoma Park, Changhee; Na, Kwon Joong; Choi, Hongyoon; Ock, Chan-Young; Ha, Seunggyun; Kim, Miso; Park, Samina; Keam, Bhumsuk; Kim, Tae Min; Paeng, Jin Chul; Park, In Kyu; Kang, Chang Hyun; Kim, Dong-Wan; Cheon, Gi-Jeong; Kang, Keon Wook; Kim, Young Tae; Heo, Dae Seog Theranostics, Vol.10 No.23, pp.10838-10848	view file DOI
2023-01	Ligand-based pharmacophore modelling in search of novel anaplastic lymphoma kinase inhibitors Gajulapalli, V. Pratap Reddy; Lee, Ju Yong; Sohn, In Suk Results in Chemistry, Vol.5, p. 100752	DOI

1